代谢组学在恶性肿瘤诊断中的应用研究进展

doi:10.3969/j.issn.1674-490X.2016.03.009

医学研究与教育 ›› 2016, Vol. 33 ›› Issue (3): 42-46.DOI: 10.3969/j.issn.1674-490X.2016.03.009

代谢组学在恶性肿瘤诊断中的应用研究进展

李雨萌¹,陈莹²

1.中国医科大学, 辽宁沈阳 110000;
2.中国医科大学附属第一医院, 辽宁沈阳 110001

收稿日期:2016-04-15 出版日期:2016-06-25 发布日期:2016-06-25
通讯作者: 陈莹(1982—),女,辽宁沈阳人,副教授,硕士,主要从事医院药学研究。E-mail: sekiwangedward@163.com
作者简介:李雨萌(1995—),女,辽宁沈阳人,主要从事临床医学研究。
基金资助:
辽宁省科学技术计划项目(2012225107);沈阳市科技计划项目(F12-277-1-79);中国医科大学附属第一医院科学技术计划项目(FSFH1217)

Advances on research of metabolomics in malignant cancer diagnosis

LI Yumeng¹,CHEN Ying²

1.China Medical University, Shenyang 110000, China; 2.The First Affiliated Hospital of China Medical University, Shenyang 110001, China

Received:2016-04-15 Online:2016-06-25 Published:2016-06-25

摘要/Abstract

摘要： 近年来代谢组学研究成为疾病诊断、疾病机制研究等的有力手段,对于生物代谢物变化的研究思想已被广泛接受。本文总结了近年来代谢组学研究在恶性肿瘤诊断中的应用,将近几年国内外代谢组学在恶性肿瘤诊断方面相关文献按病种进行归纳整理、总结分析。目前代谢组学用于肿瘤诊断主要集中在胃癌、肝癌、肺癌、食管癌、乳腺癌、卵巢癌、前列腺癌等。代谢组学在恶性肿瘤的发病机制、早期诊断、鉴别诊断、分期及预后判断方面均显示出巨大的发展潜力。随着分析技术的不断发展和完善,代谢组学将成为恶性肿瘤研究的重要手段。

关键词: 代谢组学, 癌症, 诊断, 研究进展

Abstract: Metabolomics for biological metabolite changes was widely accepted,the study of metabolomics is becoming a powerful tool for disease diagnosis and disease mechanism in recent years.In this paper,we review the recent applications of metabonomics study in the diagnosis of malignant tumor.Literatures about the study of metabonomics in the diagnosis of malignant tumor were summarized according to the classification of tumors.In recent years,metabolomics is widely used in cancer diagnosis,mainly in gastric cancer,liver cancer,lung cancer,esophageal cancer,breast cancer,ovarian cancer,prostate cancer,et al.Metabolomics play important role in the aspects of cancer pathogenesis,early diagnosis,differential diagnosis,staging and prognosis.With the development of analysis techniques,metabolomics will become an important method in the research of malignant tumor.

Key words: metabolomics, cancer, diagnosis, review

中图分类号:

李雨萌,陈莹. 代谢组学在恶性肿瘤诊断中的应用研究进展[J]. 医学研究与教育, 2016, 33(3): 42-46.

LI Yumeng,CHEN Ying. Advances on research of metabolomics in malignant cancer diagnosis[J]. Medical Reserch and Education, 2016, 33(3): 42-46.

参考文献

[1] WU H,XUE R Y,TANG Z Q,et al.Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry[J].Anal Bioanal Chem,2010,396: 1385-1395.DOI:10.1007/s00216-009-3317-4.
[2] ZHANG Y,REN H,JIANG Y,et al.Urinary metabonomics of stomach cancer assessed by rapid resolution liquid chromatography/time-of-flight mass spectrometry[J].Chinese Medical Journal,2013,126(10): 1930-1933.DOI:10.3760/cma.j.issn.0366-6999.20111240.
[3] LIANG Q,WANG C,LI B,et al.Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer [J].Appl Biochem Biotechnol.2015,176(8): 2170-2184.DOI:10.1007/s12010-015-1706-z.
[4] XIAO J F,RENCY V S,ZHOU B,et al.LC-MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort[J].J Proteome Res.2012,11(12): 5914-5923.DOI:10.1021/pr300673x.
[5] HUANG Q,TAN Y X,YIN P Y,et al.Metabolic Characterization of Hepatocellular Carcinoma Using Nontargeted Tissue Metabolomics[J].Cancer Research,2013,73: 4992-5002.DOI:10.1158/0008-5472.CAN-13-0308.
[6] LIU Y,HONG Z Y,TANG G G,et al.NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis[J].Int J Cancer,2014,135(3):658-668.DOI:10.1002/ijc.28706.
[7] XU X,CHENG S,DING C,et al.Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method.[J].Mol Med Rep,2015,11(3):2191-2198.DOI:10.3892/mmr.2014.2973.
[8] 彭媛,刘冉,李晓波,等.应用LC/TOF-MS分析食管鳞状细胞癌血浆小分子代谢物的实验研究[J].癌变·畸变·突变,2013,25(6):412-421.DOI:10.3969/j.issn.1004-616x.2013.06.002.
[9] LIU R,PENG Y,LI X B,et al.Identification of Plasma Metabolomic Profiling for Diagnosis of Esophageal Squamous-Cell Carcinoma Using an UPLC/TOF/MS Platform[J].Int J Mol Sci,2013,14:8899-8911.DOI:10.3390/ijms14058899.
[10] WU M H,XUE Y,WILLIAM L,et al.Liquid chromatography/mass spectrometry methods for measuring dipeptide abundance in non-small-cell lung cancer[J].Rapid Commun Mass Spectrom,2013,27(18):2091-8.DOI:10.1002/rcm.6656.
[11] 牛艳洁,江银玲,许长江,等.代谢组学方法分析肺癌患者血清和尿液小分子代谢产物的初步研究[J].中国肺癌杂志.2012,15(4):195-201.DOI:10.3779/j.issn.1009-3419.2012.04.01.
[12] 余欣尉,吴谦,吕望,等.基于液相色谱-质谱联用技术的肺癌细胞代谢组学分析[J].色谱.2013,31(7):691-696.DOI:10.3724/SP.J.1123.2012.12039.
[13] MIYAMOTS S,TAYLOR S L,BARUPAL D K,et al.Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry [J].Metabolites,2015,5(2):192-210.DOI:10.3390/metabo5020192.
[14] BUDCZIES J,BROCKMLLER S F,MÜLLER B M,et al.Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism[J].J Proteomics,2013,94:279-88.DOI:10.1016/j.jprot.2013.10.002.
[15] JOBARD E,PONTOIZEAU C,BLAISE B J,et al.A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer[J].Cancer Lett,2014,343(1):33-41.DOI:10.1016/j.canlet.2013.09.011.
[16] QIU Y P,ZHOU B,SU M,et al.Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid Profile in Breast Cancer Patients[J].Int.J.Mol.Sci,2013,14:8047-8061.DOI:10.3390/ijms.14048047.
[17] XIE G,ZHOU B,ZHAO A,et al.Lowered circulating aspartate is a metabolic feature of human breast cancer[J].Oncotarget,2015,6(32):33369-33381.DOI:10.18632/oncotarget.5409.
[18] FAN L J,ZHANG W,YING M Z,et al.Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform[J].Acta Oncologica,2012,51: 473-479.DOI:10.3109/0284186X.2011.648338.
[19] ZHANG T,WY X,KE C,et al.Identification of potential biomarkers for ovarian cancer by urinary metabilomic profiling[J].J Protwome Res,2013,12(1):505-512.DOI:10.1021/pr3009572.
[20] KAUSHIK A K,VAREED S K,BASU S,et al.Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer[J].J Proteome Res,2014,13(2),1088-1100.DOI:10.1021/pr401106h.
[21] MCDUNN J E,LI Z,ADAM K P,et al.Metabolomic signatures of aggressive prostate cancer[J].Prostate,2013,73(14):1547-60.DOI:10.1002/pros.22704.
[22] ZHANG T,DAVID G W,WANG L J,et al.Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery[J].PLoS One,2013,8(6):10454-10461.DOI:10.1371/journal.pone.0065880.

代谢组学在恶性肿瘤诊断中的应用研究进展

Advances on research of metabolomics in malignant cancer diagnosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张印恩,于欢欢,王键龙,胡斌,曾诚,林文哲,徐瑞轩,焦建宝. 关于戈勒姆病的研究进展[J]. 医学研究与教育, 2023, 40(5): 29-37.
[2]	冯菲,赵越,陈飞,薛丽丽. ADDIE教学模型在超声诊断学中的应用与效果评价[J]. 医学研究与教育, 2023, 40(4): 75-80.
[3]	冯长平,张卓奇,苏宇. 外泌体长链非编码RNA在胃癌中的研究进展[J]. 医学研究与教育, 2023, 40(3): 14-21.
[4]	王静,韩力,张泽明. 慢性阻塞性肺疾病相关肺动脉高压的研究进展[J]. 医学研究与教育, 2022, 39(3): 21-28.
[5]	徐莉,刘文娟,张丽. 妇科癌症患者生育忧虑状况及影响因素分析[J]. 医学研究与教育, 2022, 39(3): 67-73.
[6]	张晓凤,张一曼,张红杰. 癌症患者服用口服营养补充剂的效果[J]. 医学研究与教育, 2021, 38(5): 36-44.
[7]	朱飞, 路潜,刘春蕾,杨兰兰,石磊. 癌症患者生育忧虑概念分析[J]. 医学研究与教育, 2021, 38(5): 51-58.
[8]	李鹤飞, 王海波, 李伟, 史鸿云, 贾友超. 外周血ctDNA基因突变对早中期非小细胞肺癌患者的诊断效能分析[J]. 医学研究与教育, 2020, 37(6): 23-28.
[9]	乔薪纳,乔艳华. 疾病诊断相关分组未入组病案编码分析[J]. 医学研究与教育, 2020, 37(4): 43-48.
[10]	周雪,张玉琴,唐瑞,陈卓园园,韩兴平. 综合医院28例腹盆腔癌症终末期患者的安宁疗护实践[J]. 医学研究与教育, 2020, 37(3): 60-66.
[11]	殷小平,邢立红,张宇,马茜,李宏军. 新型冠状病毒肺炎影像学诊断指南解读[J]. 医学研究与教育, 2020, 37(2): 1-12.
[12]	沈蒙蒙,王淑梅,郝永,刘冲,张建军. 神经突定向弥散与密度成像对脑胶质瘤分级的初步诊断[J]. 医学研究与教育, 2020, 37(2): 37-43.
[13]	张彩芬,巩建萍,李云瑶,张敏聪,唐敏. 对青少年甲状腺结节的临床诊断及中医药治疗分析[J]. 医学研究与教育, 2019, 36(6): 44-47.
[14]	王霜霜,王鑫鑫,郭玉芳,徐月清,薛桂花. 癌症儿童安宁疗护影响因素及对策研究进展[J]. 医学研究与教育, 2019, 36(5): 45-51.
[15]	陈芷谦,郭巧红. 癌症姑息治疗中的尊严系列研究[J]. 医学研究与教育, 2019, 36(2): 54-61.